A New Prescription for the Opioid Epidemic: 360-Degree Accountability for Pharmaceutical Companies and Their Executives

67 Pages Posted: 21 Mar 2021 Last revised: 29 Mar 2021

Date Written: March 4, 2021

Abstract

We can no longer ignore this--A national crisis resulting in more than half-a-million American deaths, costing hundreds of millions of dollars in losses to the economy, ravaging the health care system, and devastating state and local communities. This narrative describes the COVID-19 pandemic and something else: the epidemic of opioid addiction and abuse. In the last twenty years, the opioid epidemic claimed the lives of more than 700,000 people at the cost of more than 500 billion dollars to the economy. The COVID-19 pandemic has made the opioid epidemic worse, causing a staggering increase in opioid-related overdose deaths. Even now, on average, 140 people die every day from an opioid overdose, making it a leading cause of injury-related death in the United States. And 70 percent of those deaths involve a prescription opioid.

There is a growing sense that those responsible for the opioid epidemic, specifically drug companies and their executives, have escaped responsibility for their dangerous and deceptive practices in manufacturing and marketing opioids. Although they have confronted civil lawsuits, the pharmaceutical industry has faced virtually no criminal scrutiny; only a couple of companies and executives have ever been criminally charged for the devastation that opioids have caused. This raises questions: Given the increasing number of opioid overdose deaths nationally, why are charges and convictions of drug companies and their executives so rare? And why haven’t existing legal mechanisms worked to punish the improper manufacturing and marketing practices and curb the epidemic? Their misconduct continues because no single federal law exists to prosecute pharmaceutical companies and their executives for causing the epidemic. And the laws that govern the industry are ineffective; they fail to criminalize the type of conduct that caused the epidemic, contain elements that are prohibitively difficult to prove, or impose minimal penalties that fail to deter bad actors. Thus, the drug industry has persisted in dubious practices unfettered by civil litigation, government enforcement actions, and fines. This article seeks to examine these issues and others. It is the first in legal scholarship to offer a concrete and omnibus solution grounded in federal law to address the pharmaceutical industry’s misconduct. The article also continues the conversation I began in my article, The Prescription Abuse Prevention Act: A New Federal Statute to Criminalize Overprescribing Opioids, 39 YALE L. & POL’Y REV. (forthcoming, 2021) which offered a proposal for federal criminalization of doctors who overprescribe opioids. The novel 360-degree solution proposed here—the “Controlled Substance Manufacturing and Marketing Accountability Act”--will deter and punish those pharmaceutical companies and their executives who provided misleading information to government regulators and used deceptive practices in marketing opioids to the public. It also recognizes that when properly prescribed, these drugs provide essential relief for pain and suffering. Thus, this proposal seeks to address prior misconduct and point the way forward to avoid the next drug epidemic.

Keywords: Opioid epidemic, Pharmaceutical, Criminal Law, Opioids, Pharmaceutical Executives and owners

Suggested Citation

Delfino, Rebecca, A New Prescription for the Opioid Epidemic: 360-Degree Accountability for Pharmaceutical Companies and Their Executives (March 4, 2021). Loyola Law School, Los Angeles Legal Studies Research Paper No. 2021-03, Available at SSRN: https://ssrn.com/abstract=3797972 or http://dx.doi.org/10.2139/ssrn.3797972

Rebecca Delfino (Contact Author)

Loyola Law School Los Angeles ( email )

919 Albany Street
Los Angeles, CA 90015-1211
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
112
Abstract Views
959
rank
350,479
PlumX Metrics